3-bromo-7-(triisopropylsilyloxy)chroman-4-one | 138047-39-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3-bromo-7-(triisopropylsilyloxy)chroman-4-one
• 英文别名: 3-Bromo-7-(triisopropylsilyloxy)-4-chromanone；3-bromo-7-tri(propan-2-yl)silyloxy-2,3-dihydrochromen-4-one
• CAS: 138047-39-9
• 化学式: C₁₈H₂₇BrO₃Si
• 分子量: 399.4
• InChiKey: MLNVYYWVCITBMV-UHFFFAOYSA-N

物化性质

• 沸点：
  420.9±45.0 °C(Predicted)
• 密度：
  1.206±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.58
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-苯基-4-羟基哌啶 、 3-bromo-7-(triisopropylsilyloxy)chroman-4-one 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 反应 1.0h， 以34%的产率得到(E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxy-4-phenylpiperidin-1-yl)prop-2-en-1-one
  参考文献：
  名称：

  Synthesis and dopaminergic activity of some E-3-(piperidin-1-yl)-1-(4-substituted phenyl)prop-2-en-1-one derivatives

  摘要：

  A convenient route for the synthesis of some 2-propen-1-one derivatives with E isomeric configuration is described. The activity of the synthesized compounds was evaluated through behavioral studies of apomorphine-induced licking in animal models. It was demonstrated that most of the synthesized compounds showed moderate activity in inhibition of lickings, among which 6a, was the most active compound at 30 mg/kg. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.08.030
• 作为产物：
  描述：

  7-(triisopropylsilyloxy)-4-chromanone 在 copper(ll) bromide 作用下， 以 氯仿 、 乙酸乙酯 为溶剂， 反应 5.0h， 以60%的产率得到3-bromo-7-(triisopropylsilyloxy)chroman-4-one
  参考文献：
  名称：

  Synthesis and dopaminergic activity of some E-3-(piperidin-1-yl)-1-(4-substituted phenyl)prop-2-en-1-one derivatives

  摘要：

  A convenient route for the synthesis of some 2-propen-1-one derivatives with E isomeric configuration is described. The activity of the synthesized compounds was evaluated through behavioral studies of apomorphine-induced licking in animal models. It was demonstrated that most of the synthesized compounds showed moderate activity in inhibition of lickings, among which 6a, was the most active compound at 30 mg/kg. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.08.030

文献信息

• Method of treating diseases susceptable to treatment by blocking
  申请人：Pfizer Inc.

  公开号：US05436255A1

  公开（公告）日：1995-07-25

  3-Piperidino-1-chromanol derivatives and analogs having the formula ##STR1## wherein A and B are taken together and are --CH.sub.2 CH.sub.2 -- or A and B are taken separately and are each H; X is CH.sub.2 or O; X.sup.1 is H or OH; Z is H, F, Cl, Br or OH; Z.sup.1 is H, F, Cl, Br or (C.sub.1 -C.sub.3)alkyl; n is 0 or 1; and m is 0 or an integer from 1 to 6; pharmaceutical compositions thereof; methods of treating CNS disorders therewith; and intermediates useful in the preparation of said compounds are disclosed.

  本发明涉及3-哌啶基-1-色甘醇衍生物和类似物，其具有以下式子：##STR1## 其中，A和B在一起取-CH.sub.2 CH.sub.2-，或A和B分别取H；X为CH.sub.2或O；X.sup.1为H或OH；Z为H、F、Cl、Br或OH；Z.sup.1为H、F、Cl、Br或(C.sub.1-C.sub.3)烷基；n为0或1；m为0或1至6之间的整数；以及其制药组合物，用于治疗中枢神经系统疾病的方法，以及用于制备所述化合物的中间体。
• Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
  申请人：Pfizer Inc.

  公开号：US05356905A1

  公开（公告）日：1994-10-18

  3-Piperidino-1-chromanol derivatives and analogs having the formula ##STR1## wherein A and B are taken together and are --CH.sub.2 CH.sub.2 -- or A and B are taken separately and are each H; X is CH.sub.2 or O; X.sup.1 is H or OH; Z is H, F, Cl, Br or OH; Z.sup.1 is H, F, Cl, Br or (C.sub.1 -C.sub.3)alkyl; n is 0 or 1; and m is 0 or an integer from 1 to 6; pharmaceutical compositions thereof; methods of treating CNS disorders therewith; and intermediates useful in the preparation of said compounds.

  具有以下式子的3-哌啶基-1-色酚衍生物和类似物：##STR1## 其中A和B在一起为--CH.sub.2 CH.sub.2 --或A和B分别为H；X为CH.sub.2或O；X.sup.1为H或OH；Z为H，F，Cl，Br或OH；Z.sup.1为H，F，Cl，Br或（C.sub.1 -C.sub.3）烷基；n为0或1；m为0或1至6的整数；其药物组成物；用于治疗中枢神经系统疾病的方法；以及用于制备所述化合物的中间体。